ETON
Eton Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$58.45
−2.42%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 105.6M | 80.0M | 39.0M | 31.6M | 21.3M |
| Cost of Revenue | 44.5M | 37.2M | 15.6M | 10.6M | 6.9M |
| Gross Profit | 61.1M | 42.7M | 23.4M | 21.1M | 14.3M |
| Operating Expenses | |||||
| R&D Expense | 5.8M | 7.8M | 3.3M | 3.3M | 4.0M |
| SG&A Expense | 39.0M | 35.8M | 22.8M | 18.9M | 18.6M |
| General & Admin Expense | 39.0M | 35.8M | 22.8M | 18.9M | 18.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | (916.0K) | — | — | — |
| Total Operating Expenses | 44.8M | 42.7M | 26.0M | 22.3M | 22.6M |
| Cost and Expenses | 89.3M | 79.9M | 41.6M | 32.8M | 29.5M |
| Operating Income (EBIT) | 16.3M | 72.0K | (2.6M) | (1.2M) | (8.3M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 2.7M | 4.8M | 2.0M | 1.1M | 955.0K |
| Net Interest Income | (2.7M) | (4.8M) | (2.0M) | (1.1M) | (955.0K) |
| Other Non-Op Income/Expense | (3.6M) | (4.6M) | (1.2M) | 503.0K | (761.0K) |
| Non-Operating Income (excl Interest) | 902.0K | (151.0K) | (794.0K) | (503.0K) | 761.0K |
| EBT (Pre-Tax Income) | 12.8M | (4.6M) | (3.8M) | (689.0K) | (9.0M) |
| Income Tax Expense | 63.0K | 43.0K | 15.0K | 247.0K | — |
| Bottom Line | |||||
| Net Income | 12.7M | (4.6M) | (3.8M) | (936.0K) | (9.0M) |
| Earnings from Cont. Ops | 12.7M | (4.6M) | (3.8M) | (936.0K) | (9.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 12.7M | (4.6M) | (3.8M) | (936.0K) | (9.0M) |
| Per Share | |||||
| Basic EPS | $0.47 | ($0.17) | ($0.15) | ($0.04) | ($0.36) |
| Diluted EPS | $0.38 | ($0.17) | ($0.15) | ($0.04) | ($0.36) |
| Revenue Per Share | $3.82 | $2.97 | $1.51 | $1.23 | $0.85 |
| Shares | |||||
| Basic Shares Outstanding | 27.6M | 26.9M | 25.9M | 25.6M | 25.1M |
| Diluted Shares Outstanding | 32.8M | 26.9M | 25.9M | 25.6M | 25.1M |
| Profitability Metrics | |||||
| EBITDA | 18.6M | 4.3M | (657.0K) | 212.0K | (7.2M) |
| D&A | 3.2M | 4.0M | 1.1M | 901.0K | 1.8M |
| EBIT | 15.4M | 223.0K | (1.8M) | (689.0K) | (9.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026